Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
| ▸ | NR1H4 | Q96RI1 | 11/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.42 |
| ▸ | PIK3R2 | O00459 | 1/20 | 0.42 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.42 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.42 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.42 |
| ▸ | PIK3R5 | Q8WYR1 | 1/20 | 0.42 |
| ▸ | PIK3R3 | Q92569 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2549040 | 0.88 | TP53 (0.55) | MAPTNR1H4KDM4EALDH1A1TP53 | |
| SCHEMBL2173369 | 0.87 | NR1H4 (0.53) | MAPTNR1H4POLBPIK3CDPIK3R2 | |
| SCHEMBL22299180 | 0.86 | NR1H4 (0.57) | MAPTNR1H4TP53POLB | |
| SCHEMBL2189673 | 0.79 | TP53 (0.55) | MAPTNR1H4KDM4EALDH1A1TP53 | |
| SCHEMBL2546279 | 0.78 | MAPT (0.55) | MAPTNR1H4KDM4EALDH1A1TP53 | |
| SCHEMBL2171176 | 0.78 | MAPT (0.46) | MAPTNR1H4TP53POLBPIK3CD | |
| SCHEMBL21574265 | 0.76 | THRB (0.43) | MAPTNR1H4KDM4EALDH1A1GAA | |
| SCHEMBL21574194 | 0.76 | THRB (0.43) | MAPTNR1H4KDM4EALDH1A1GAA | |
| SCHEMBL19810692 | 0.76 | TP53 (0.55) | MAPTNR1H4TP53POLBPIK3CD | |
| SCHEMBL19810671 | 0.76 | NR1H4 (0.48) | MAPTNR1H4KDM4EALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11021446-B2 | Compositions and methods for modulating farnesoid X receptors | NOVARTIS AG (CH) | 2021-06-01 | — | — | US | disclosed |
| US-20200247757-A1 | COMPOSITIONS AND METHODS FOR MODULATING FARNESOID X RECEPTORS | NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC. | 2020-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11021446-B2 | Compositions and methods for modulating farnesoid X receptors | NR1H4, GPBAR1, SLC10A1 | MAPT 4447/4885NR1H4 1/4885KDM4E 3954/4885 |
| US-20200247757-A1 | COMPOSITIONS AND METHODS FOR MODULATING FARNESOID X RECEPTORS | NR1H4, GPBAR1, SLC10A1 | MAPT 4447/4885NR1H4 1/4885KDM4E 3954/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.